EYSUVIS

Peak

loteprednol etabonate

NDAOPHTHALMICSUSPENSION/DROPS
Approved
Oct 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10

Mechanism of Action

healing. Corticosteroids inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the…

Clinical Trials (5)

NCT03531697Phase 1Completed

Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery

Started Apr 2018
NCT02208297Phase 3Completed

Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Started Sep 2014
326 enrolled
InflammationPainCataract
NCT01736527Phase 1Completed

Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

Started Jan 2013
12 enrolled
Pharmacokinetics
NCT01695668N/ACompleted

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%

Started Aug 2011
75 enrolled
Dry Eyes
NCT01384266N/ACompleted

A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery

Started May 2010
90 enrolled
Intraocular Inflammation

Loss of Exclusivity

LOE Date
May 3, 2033
87 months away
Patent Expiry
May 3, 2033

Patent Records (5)

Patent #ExpiryTypeUse Code
10058511
May 3, 2033
Product
U-2492
10646436
May 3, 2033
Product
10688045
May 3, 2033
Product
10857096
May 3, 2033
U-2985
10940108
May 3, 2033
U-2985